- Report
- April 2025
- 175 Pages
Global
From €3980EUR$4,490USD£3,460GBP
- Report
- February 2025
- 240 Pages
Global
From €2384EUR$2,690USD£2,073GBP
- Report
- July 2025
- 175 Pages
Global
From €3980EUR$4,490USD£3,460GBP
- Report
- March 2025
- 150 Pages
Global
From €2881EUR$3,250USD£2,504GBP
€4299EUR$4,850USD£3,737GBP
- Report
- July 2025
- 483 Pages
Global
From €5185EUR$5,850USD£4,508GBP
- Report
- July 2025
- 485 Pages
Global
From €5185EUR$5,850USD£4,508GBP
- Report
- July 2025
- 377 Pages
Global
From €5185EUR$5,850USD£4,508GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1108EUR$1,250USD£963GBP
- Report
- August 2024
- 233 Pages
Global
From €7047EUR$7,950USD£6,126GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €2216EUR$2,500USD£1,926GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2472EUR$2,789USD£2,149GBP
- Report
- June 2025
- 200 Pages
United States
From €2207EUR$2,490USD£1,919GBP
- Report
- August 2022
- 115 Pages
Global
From €3989EUR$4,500USD£3,468GBP
- Report
- May 2024
- 135 Pages
Global
From €5761EUR$6,499USD£5,008GBP
- Report
- May 2024
- 132 Pages
Global
From €5761EUR$6,499USD£5,008GBP
- Report
- May 2024
- 138 Pages
Global
From €5761EUR$6,499USD£5,008GBP
- Report
- May 2024
- 128 Pages
Global
From €5761EUR$6,499USD£5,008GBP
- Report
- June 2024
- 185 Pages
Global
From €3390EUR$3,825USD£2,948GBP
€3989EUR$4,500USD£3,468GBP
- Report
- January 2024
- 395 Pages
Global
From €6648EUR$7,500USD£5,779GBP
- Report
- August 2022
- 30 Pages
Global
From €2438EUR$2,750USD£2,119GBP

Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more